Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

458.99 +5.82 (+1.28%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
66 67 Next >
News headline image
The Best Biotech Stocks to Buy in 2026 ↗
They have at least one thing in common: An exciting pipeline. 
Via The Motley Fool
Topics ETFs
News headline image
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? ↗
A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct financials and risk profiles shaping their 2026 outlook. 
Via The Motley Fool
News headline image
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus? ↗
The company seems to be doing everything it's supposed to be doing; the stock just isn't responding. 
Via The Motley Fool
VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX): Affordable Growth with Strong Fundamentals ↗
Via Chartmill
Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth Meets a Technical Setup for a Potential Breakout ↗
Via Chartmill
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Fits the Affordable Growth Profile With Strong Earnings and Reasonable Valuation ↗
Via Chartmill
Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q1 Estimates as New Drug Launches Drive Diversification ↗
Via Chartmill
News headline image
The Best Stocks to Invest $500 in Right Now ↗
The market is underestimating these companies' long-term prospects. 
Via The Motley Fool
News headline image
2 Healthcare Stocks with Exciting Potential and 1 Facing Challenges
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloade... 
Via StockStory
News headline image
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? ↗
Are there significant gains ahead for one (or both) of these innovative biotechs? 
Via The Motley Fool
Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth Stock with Promising Technical Setup ↗
Via Chartmill
Which S&P500 stocks are moving on Tuesday? ↗
Via Chartmill
News headline image
1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist? ↗
The biotech's innovative platform could pay off. 
Via The Motley Fool
News headline image
5 Must-Read Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call
Vertex Pharmaceuticals' first quarter results reflected balanced growth across its cystic fibrosis franchise and newly launched therapies, with management hi... 
Via StockStory
Topics Earnings
News headline image
Is This Millionaire-Maker Biotech Stock a Buy Right Now? ↗
The market wasn't impressed by its latest quarterly update. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Vertex (VRTX) Q1 2026 Earnings Call Transcript ↗
Vertex (VRTX) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Vertex Pharmaceuticals Reports Mixed Q1 Results ↗
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reports financial results for the first quarter after the market close on Monday. 
Via Benzinga
News headline image
Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q1 CY2026 Sales Expectations
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 7.8% year on year to $2.99 billion. ... 
Via StockStory
News headline image
Vertex (VRTX) Q2 2025 Earnings Call Transcript ↗
Vertex (VRTX) Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Vertex Pharmaceuticals (VRTX) Q1 Earnings: What To Expect
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here’s what investors should know. Vertex Pharmace... 
Via StockStory
News headline image
Got $1,000? Which of These Beaten-Down Healthcare Stocks Is Worth Buying? ↗
These longtime market beaters may not have peaked yet. 
Via The Motley Fool
Topics World Trade
News headline image
Set It and Forget It: 3 Monster Stocks Worth Holding Through Whatever Comes Next ↗
They may suffer the occasional knee-jerk setback. By and large, though, investors understand these companies are capable of standing up to almost any challenge. 
Via The Motley Fool
Topics Credit Cards Economy
News headline image
Want to Build Real Wealth in Healthcare? These Stocks Are Worth Considering ↗
These companies are leaders in their fields. 
Via The Motley Fool
News headline image
What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer. ↗
The biotech's candidate may treat a great number of illnesses that have one thing in common. 
Via The Motley Fool
News headline image
Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead? ↗
This particular player has seen its yield rise in recent years. 
Via The Motley Fool
News headline image
3 Growth Stocks That Could Generate 10X Returns ↗
These stocks come with risk, but they also have some exciting long-term growth opportunities. 
Via The Motley Fool
Topics Cannabis Law Enforcement
News headline image
3 of Wall Street’s Favorite Stocks Worth Your Attention
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
News headline image
3 Market-Beating Stocks to Consider Right Now
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ... 
Via StockStory
Topics Energy
News headline image
3 Healthcare Stocks With the Most Durable Competitive Moats ↗
These companies offer a clear path to sustained earnings growth. 
Via The Motley Fool
Topics Intellectual Property
News headline image
CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy? ↗
We'll know more about the company's medium-term prospects by the end of the year. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
66 67 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.